AI Article Synopsis

  • * Left ventricular non-compaction (LVNC) is another condition characterized by excessive trabeculation in the left ventricle, commonly found in about 5% of the population and usually benign, but can sometimes cause heart function problems or lead to blood clots.
  • * Recent studies suggest a significant overlap between HCM and LVNC, including shared genetic factors, raising questions about whether they are different manifestations of the same disease or separate

Article Abstract

Hypertrophic cardiomyopathy (HCM) is a genetically determined myocardial disease characterized by an increased thickness of the left ventricle (LV) wall that cannot be solely attributed to abnormal loading conditions. HCM may present with an intraventricular or LV outflow tract obstruction, diastolic dysfunction, myocardial fibrosis and/or ventricular arrhythmias. Differentiating HCM from other diseases associated with LV hypertrophy, such as hypertension, aortic stenosis, or LV non-compaction (LVNC), can at times be challenging. LVNC is defined by excessive LV trabeculation and deep recesses between trabeculae, often accompanied by increased LV myocardial mass. Previous studies indicate that the LVNC phenotype may be observed in up to 5% of the general population; however, in most cases, it is a benign finding with no impact on clinical outcomes. Nevertheless, LVNC can occasionally lead to LV systolic dysfunction, manifesting as a phenotype of dilated or non-dilated left ventricular cardiomyopathy, with an increased risk of thrombus formation and arterial embolism. In extreme cases, where LVNC is associated with a very thickened LV wall, it can even mimic HCM. There is growing evidence of an overlap between HCM and LVNC, including similar genetic mutations and clinical presentations. This raises the question of whether HCM and LVNC represent different phenotypes of the same disease or are, in fact, two distinct entities.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439099PMC
http://dx.doi.org/10.4330/wjc.v16.i9.496DOI Listing

Publication Analysis

Top Keywords

hypertrophic cardiomyopathy
8
left ventricular
8
hcm lvnc
8
lvnc
7
hcm
6
cardiomyopathy left
4
ventricular non-compaction
4
non-compaction distinct
4
distinct diseases
4
diseases variant
4

Similar Publications

Background: Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy and causes major adverse cardiovascular events (MACE). SVEP1 (Sushi, von Willebrand factor type A, epidermal growth factor, and pentraxin domain containing 1) is a large extracellular matrix protein that is detectable in the plasma. However, it is unknown whether adding plasma SVEP1 levels to clinical predictors including NT-proBNP (N-terminal pro-B-type natriuretic peptide) improves the prognostication in patients with hypertrophic cardiomyopathy.

View Article and Find Full Text PDF

CCL2-CCR2 axis in cardiovascular disease: Research advances and challenges.

Sci Bull (Beijing)

January 2025

Xijing Hypertrophic Cardiomyopathy Center, Department of Ultrasound, Xijing Hospital, The Airforce Military Medical University, 127 Changle West Road, Xi'an 710032, China. Electronic address:

View Article and Find Full Text PDF

Recent development in CRISPR-Cas systems for cardiac disease.

Prog Mol Biol Transl Sci

January 2025

Department of Microbiology, Gargi College, University of Delhi, New Delhi, India. Electronic address:

The CRISPR-Cas system has emerged as a revolutionary tool in genetic research, enabling highly precise gene editing and significantly advancing the field of cardiovascular science. This chapter provides a comprehensive overview of the latest developments in utilizing CRISPR-Cas technologies to investigate and treat heart diseases. It delves into the application of CRISPR-Cas9 for creating accurate models of complex cardiac conditions, such as hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and various arrhythmias, which are essential for understanding disease mechanisms and testing potential therapies.

View Article and Find Full Text PDF

Sengers Syndrome (SS) is a rare autosomal recessive mitochondrial disorder caused by mutations in the acylglycerol kinase (AGK) gene on chromosome 7, also known as cardiomyopathic mitochondrial DNA depletion syndrome (MTDPS10). This disorder disrupts mitochondrial DNA function and energy metabolism, presenting with symptoms such as congenital cataracts, hypertrophic cardiomyopathy, skeletal myopathy, exercise intolerance, and lactic acidosis. Previous research has shown SS affects oxidative phosphorylation and mitochondrial respiration, implicating the TIM22 complex and carrier import.

View Article and Find Full Text PDF

Left ventricular outflow tract (LVOT) obstruction is mostly caused by hypertrophic obstructive cardiomyopathy and subaortic stenosis. Rarely, malignancy can lead to dynamic LVOT obstruction and has only been sporadically documented. We present the first case of dynamic and/or nearly fixed LVOT obstruction caused by a cardiac myxoid spindle cell sarcoma.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!